stockrow
Friday 6 November 2026
Export SEPN’s income statement to Excel — free account
Septerna, Inc.
SEPN Healthcare Biotechnology
Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.
- Revenue
- +22,375.6%
- EPS
- +48.2%
- Free cash flow
- −9.01%
Quarter to June 2026, against a year earlier
49.88
2.53
+5.34%
Follow SEPN
Alert me
Septerna, Inc. (SEPN) Operating margin
Septerna, Inc.'s operating margin over the twelve months to 30 June 2026 was −44.0%, up 104.6 percentage points from fiscal 2025 (−148.6%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Operating margin, annual
Embed this chart
Annual newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| FY2025 | −148.6% | 7,369.79 |
| FY2024 | −7,518.4% | (8,892.59) |
| FY2023 | 1,374.2% | — |
Quarterly newest first
| Period | Operating margin | Change (points) |
|---|---|---|
| Jun 2026 | −63.0% | (12.80) |
| Mar 2026 | −50.2% | 16.29 |
| Dec 2025 | −66.4% | (78.60) |
| Sep 2025 | 12.2% | 24,363.42 |
| 7 more quarters | Free account |
Operating margin against peers
| Company | Operating margin |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 44.8% |
| VCEL Vericel Corporation compare | 8.32% |
| IMNM Immunome, Inc. compare | 0.00% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| BHVN Biohaven Ltd. compare | 0.00% |
| PVLA Palvella Therapeutics, Inc. compare | 0.00% |
| SEPN Septerna, Inc. | −44.0% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −90.1% |
| ZYME Zymeworks Inc. compare | −419.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Operating margin is
EBIT Margin tells an investor how much operating profit, before interest and taxes, a company keeps from each unit of revenue.
EBIT ÷ Revenue
More on SEPN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- The full statement